**Improving the oncological outcomes of cystectomy**

**Poster Session 43**

**Sunday 17 March**
14:00 - 15:30

**Location:** Green Area, Room 3

**Chairs:**
- P. Gontero, Turin (IT)
- Y. Lotan, Dallas (US)
- M.S. Michel, Mannheim (DE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

**600**

**The natural history of untreated muscle-invasive bladder cancer**

By: Martini A.¹, Renström-Koskela L.², Morteza A.², Hosseini A.², Mehrazin R.¹,
Galsky M.¹, Sfakianos J.¹, Steineck G.³, Wiklund N.¹

¹Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America,
²Karolinska Institutet, Dept. of Molecular Medicine and Surgery, section of Urology, Stockholm, Sweden,
³University of Göteborg, Sahlgrenska Academy Clinical Sciences, Stockholm, Sweden

**Aims and objectives of this presentation**

600

---

**601**

**Withdrawn**

To be confirmed

**Aims and objectives of this presentation**

601

---

**602**

**Survival outcomes and salvage treatments for local bladder cancer recurrences following radical cystectomy**

By: Soligo M.¹, Colicchia M.¹, Morlacco A.¹, Boeri L.², Sharma V.², Frank I.²,
Boorjian S.², Karnes R.J.²

¹University of Padua, Dept. of Urology, Padua, Italy,
²Mayo Clinic, Dept. of Urology, Rochester, United States of America

**Aims and objectives of this presentation**

602

---

**603**

**Risk factors of urethral recurrence in men after radical cystectomy with orthotopic urinary diversion for urothelial carcinoma**

By: Song W.¹, Jeong J.Y.², Kim T.H.³, Yoon H.S.¹, Kim K.H.¹, Yoon H.¹, Chung W.S.¹,
Sim B.S.¹, Lee D.H.¹

¹Ewha Womans University School of Medicine, Dept. of Urology, Seoul, South Korea,
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>603</td>
<td>Clinical outcomes of tetra-modality bladder sparing therapy incorporating consolidative partial cystectomy in muscle-invasive bladder cancer patients with hydronephrosis</td>
<td>Toide M., Kijima T., Fukuda S., Fukushima H., Moriyama S., Uehara S., Yasuda Y., Yoshida S., Yokoyama M., Ishioka J., Matsuoka Y., Saito K., Kihara K., Fuji Y. Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan</td>
<td>Kangbuk Samsung Hospital, Dept. of Urology, Seoul, South Korea, CHA Bundang Medical Center, Dept. of Urology, Seongnam, South Korea</td>
</tr>
<tr>
<td>604</td>
<td>A novel nomogram to identify patients with lymph node metastases in the extended lymph node dissection area at radical cystectomy</td>
<td>Moschini M., Zamboni S., Mattei A., Baumeister P., Burgio G., Shariat S.F., Dell’Oglio P., Zaffuto E., Salonia A., Montorsi F., Briganti A., Colombo R., Gallina A.</td>
<td>IRCCS Ospedale San Raffaele; URI, Unit of Urology, Division of Oncology, Milan, Italy, Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, Medical University of Vienna, Dept. of Urology, Vienna, Austria</td>
</tr>
<tr>
<td>605</td>
<td>Standard vs extended pelvic lymph node dissection: Peri-operative complications and survival outcomes following radical cystectomy</td>
<td>Soligo M., Morlacco A., Colicchia M., Boeri L., Sharma V., Frank I., Boorjian S., Karnes R.J.</td>
<td>University of Padua, Dept. of Urology, Padua, Italy, Mayo Clinic, Dept. of Urology, Rochester, United States of America</td>
</tr>
<tr>
<td>606</td>
<td>Attributable fraction for the risk of death in patients with clinically localized muscle-invasive bladder cancer</td>
<td>Audenet F., Ferket B.S., Waingankar N., Jia R., Galsky M.D., Sfakianos J.P.</td>
<td>Hôpital Européen Georges Pompidou, Dept. of Urology, Paris, France, Icahn School of Medicine at Mount Sinai, Institute for Healthcare Delivery Science, Dept. of Population Health Science and Policy, New York, United States of America, Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, Icahn School of Medicine at Mount Sinai, Institute for Healthcare Delivery Science, Dept. of Population Health Science and Policy, New York, United States of America, Icahn School of Medicine at Mount Sinai, Institute for Healthcare Delivery Science, Dept. of Population Health Science and Policy, New York, United States of America</td>
</tr>
</tbody>
</table>
Aims and objectives of this presentation

Conservative management following non-invasive down-staging with neoadjuvant chemotherapy for muscle-invasive bladder cancer patients refusing radical cystectomy

By: Onishi T., Sekito S., Terabe T., Shibahara T.
Ise Red cross hospital, Dept. of Urology, Ise, Japan

Aims and objectives of this presentation

Incidence and impact of histological variants on survival in candidates for radical cystectomy: Results from a multicenter collaboration

By: Moschini M. 1, Zamboni S. 1, Karnes J.R. 2, Roghmann F. 3, Sargs P. 4, Montorsi F. 5, Briganti A. 5, Colombo R. 5, Gallina A. 5, Mattei A. 1, Baumeister P. 1, Rink M. 6, Poyet C. 7, Saba K. 8, Di Trapani E. 9, De Cobelli O. 9, Antonelli A. 10, Simeone C. 10, Boeri L. 2, Soligo M. 11, Simone G. 12, Gallucci M. 12, Aziz A. 13, Xylinas E. 14, Shariat S.F. 15, On behalf of the European Association of Urology - Young Accademic Urologists (EAU-YAU), Utothelial carcinoma working group and of the EAU Research Foundation
1 Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, 2 Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3 Ruhr-University Bochum, Marien Hospital, Dept. of Urology, Herne, Germany, 4 Institut Bergonié, Dept. of Radiation Therapy, Bordeaux, France, 5 Urological Research Institute, San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, 6 University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 7 University Hospital Zürich, University of Zürich, Dept. of Urology, Zürich, Switzerland, 8 University Hospital Zürich, University of Zürich, Dept. of Urology, Zürich, Switzerland, 9 European Institute of Oncology, Dept. of Urology, Milan, Italy, 10 Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy, 11 Mayo Clinic, Dept. of Urology, Rochester, United States of America, 12 IRCCS, Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 13 University Medical Center Rostock, Dept. of Urology, Rostock, Germany, 14 Bichat Hospital, Paris Descartes University, Dept. of Urology, Paris, France, 15 Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria

Aims and objectives of this presentation

Comparison of different treatment modalities outcomes in clinically node-positive bladder cancer; analysis of a population-based cancer registry.

By: Stanik M. 1, Poprach A. 2, Malúšková D. 3, Zapletalová M. 3, Macík D. 1, Čapák I. 1, Jarkovský J. 3, Lakomý R. 2, Doležel J. 1
1 Masaryk Memorial Cancer Institute, Dept. of Urologic Oncology, Brno, Czech Republic, 2 University Hospital Olomouc, Dept. of Urology, Olomouc, Czech Republic, 3 University Hospital Olomouc, Dept. of Urology, Olomouc, Czech Republic.
### 610

**Minimal invasive surgery and brachytherapy as bladder preserving multimodality treatment in selected solitary MIBC**

By: Smits G.A.H.J.\(^1\), Van Der Steen-Banasik E.\(^2\), Oosterveld B.\(^2\), Weijerman P.C.\(^1\), Kroon B.\(^1\), Haverkort D.\(^2\), Wijburg C.J.\(^1\)

\(^1\)Rijnstate Hospital Arnhem, Dept. of Urology, Arnhem, The Netherlands, \(^2\)RadioTherapieGroep, Dept. of Radiotherapy, Arnhem, The Netherlands

**Aims and objectives of this presentation**

610

---

### 611

**Global assessment of outcomes of robot-assisted radical cystectomy with orthotopic neobladder: Trifecta vs pentafecta**

By: Simone G. , Guaglianone S. , Gallucci M. , Tuderti G. , Anceschi U. , Misuraca L. , Ferriero M. , Brassetti A. , Minisola F. , Flammia R.S. , Mastroianni R.

Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

**Aims and objectives of this presentation**

611

---

### 612

**Impact of lymph node dissection in radical cystectomy for bladder cancer: How many vs how far?**


Asan Medical Center, Dept. of Urology, Seoul, South Korea

**Aims and objectives of this presentation**

612

---

### 613

**Molecular markers (FGFR3 mutation; p53 and Ki-67 expression) and clinical outcome of radical cystectomy for bladder cancer: A multi-center, multi-laboratory study**

By: Van Rhijn B.W.G.\(^1\), Mertens L.\(^1\), Mayr R.\(^2\), Bostrom P.\(^3\), Shariat S.F.\(^4\), Zwarthoff E.C.\(^5\), Boormans J.L.\(^6\), Abas C.\(^5\), Van Leenders G.\(^5\), Neuzillet Y.\(^7\), Van Der Heijden M.S.\(^1\), Jewett M.A.S.\(^8\), Stohr R.\(^9\), Zlotta A.R.\(^8\), Eckstein M.\(^9\), Sooorjebally Y.\(^10\), Burger M.\(^11\), Radvanyi F.\(^10\), Sirab N.\(^10\), Van Der Kwast T.H.\(^12\), Hartmann A.\(^9\), Lotan Y.\(^4\), Allory Y.\(^10\), Zuiverloon T.\(^6\)

\(^1\)The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Surgical Oncology, Urology, Amsterdam, The Netherlands, \(^2\)Caritas St Joseph Medical Center, University of Regensburg, Dept. of Urology, Regensburg, Germany, \(^3\)University of Turku,
Aims and objectives of this presentation